MAPT and Alzheimer disease: For example, of 14 MCI patients who developed AD during a follow-up period of 3–12 years, the 50% of patients with the highest CSF t-tau and p-tau at baseline progressed to AD within a shorter timeframe than those with levels in the lowest 50% [122].